TMA Precision Health
Making a Difference in Rare Disease Management

Joshua Resnikoff, CEO, TMA Precision Health

Amidst such a challenging scenario, TMA Precision Health arrives as a panacea for rare disease sufferers and their physicians looking to provide options for addressing rare conditions. Equipped with AI-enabled software that uses natural language processing to connect to more than 70 databases, TMA is the clinical decision support platform that gives health systems the power to unlock therapies for rare disease patients. “We believe that the patients who suffer most deserve access to the best that medicine can provide,” says Joshua Resnikoff, CEO, TMA Precision Health.

TMA’s patient-first, AI-enabled platform curates all available medical science to power its patient-specific therapeutic guidance. TMA’s clinical decision support tool condenses research from months to minutes, outputting a precision care plan that has therapeutic recommendations that can be accessed by patients as well as clinicians. TMA is focused on making sure both the doctor and the patient come away with the right information they need to inform their care plan. “We can present that information at a high level that makes sense to the doctors, but also at a general enough level that patients can understand, internalize, and make it actionable in their daily life,” Resnikoff states.

A Patient-Centric Approach

While other rare disease patient advocacy and clinical trial matching companies dot the market, TMA’s focus on rare disease therapeutic guidance is unique in the industry. “No one else provides health systems the means to access the full gamut of treatment options, including purposed and repurposed drugs so that patients can get the best medicine possible,” Resnikoff remarks. TMA’s approach is a direct result of the frustration the founders experienced having been affected by rare disease – either personally, or through a family member. Be it TMA’s co-founder and Chief Innovation Officer Lina Williamson’s struggle to manage her Ehlers-Danlos syndrome, or Resnikoff’s search for a way to manage his son’s unexplained periodic fever bouts, rare disease management is a close-at-heart matter for TMA’s leadership.

We believe that the patients who suffer most deserve access to the best that medicine can provide

To this end, TMA is further automating the platform to give doctors even better AI-enabled rare care superpowers. As more doctors use the platform, TMA is building a database of patient information and real-world evidence that powers a virtuous circle of better therapies and standards of care globally.

These therapies will then be leveraged for the direct positive benefit for the individual patient. “The focus right now is to scale up our international deployment so that we are creating true change for patients everywhere,” Resnikoff says.

Intending to expand its services beyond the US, TMA has partnered with Ion Health – the Precision Medicine Institute of Latin America in Medellin, Colombia, where they conducted a field trial to showcase the effectiveness of its offerings on a group of randomly selected patients with a confirmed rare disease diagnosis by a local health insurance company. The patients had attempted an average of 22 different medications, with limited success. TMA’s clinical decision support platform was able to achieve a 95 percent success rate in identifying suitable medical interventions for the patients. Driven by such positive results, TMA is looking to expand its services to other health systems that would benefit from adding such a powerful tool to their toolbox.

Going forward, TMA has its hands full with exciting developments on its roadmap. Seeking to build on its success in Columbia, TMA is looking for a domestic partner in the United States and intends to take its platform to Sub-Saharan Africa. Talks with a Korean group offering rare disease genetic testing are also underway. Keeping its mission of alleviating patient suffering at the forefront, TMA is working with one of the largest curators of genetic information on the web to create a patient-facing, rare disease information portal where patients can get access to basic therapeutic information if their local health system has not yet onboarded TMA’s software. TMA intends to make its clinical decision support tools as easy to use as Google and as informative as Wikipedia, according to Resnikoff. “Our goal is to be the de facto global brand for rare disease therapeutic guidance,” he adds. By focusing on improving rare disease care today while building a database to power therapies for tomorrow, TMA will continue to put rare disease patients at the focus of everything it does.